SARS: una nueva enfermedad desenmascarada

por Pareja Bezares, A., Torán Mateos, M.
Publicado 2003

PB2004: BCMA-DIRECTED THERAPY FOR MULTIPLE MYELOMA: EFFECTIVENESS OF ONLINE EDUCATION IN IMPROVING KNOWLEDGE AND COMPETENCE IN PRACTICAL APPLICATION

por Harvey-Jones, V., Koekkoek, S., Vandenbroucque, J., Mateos, M.-V.
Publicado 2022

Evolución y calidad de vida a los tres meses tras hospitalización por neumonía COVID

por Valverde Mateos, M.P., González Romero, A., Alvarado Ramos, V., Miangolarra Page, J.C.
Publicado 2022

P38 PATIENT-REPORTED OUTCOMES (PRO) IN RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM) TREATED WITH MELFLUFEN AND DEXAMETHASONE (DEX) OR POMALIDOMIDE (POM) AND DEX: ANALYSES FROM THE P...

por Schjesvold, F, Ludwig, H, Delimpasi, S, Robak, P, Mateos, M, Sandberg, A, Thuresson, M, Norin, S, Richardson, P, Sonneveld, P
Publicado 2023

Prediction of 30-day unplanned hospital readmission through survival analysis

por Pons-Suñer, Pedro, Arnal, Laura, Signol, François, Caballero Mateos, M. Jose, Valdivieso Martínez, Bernardo, Perez-Cortes, Juan-Carlos
Publicado 2023

P907: CARFILZOMIB, DEXAMETHASONE, AND DARATUMUMAB (KDD) VS CARFILZOMIB AND DEXAMETHASONE (KD) IN RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM): FRAILTY SUBGROUP ANALYSIS OF THE CANDO...

por Quach, H., Leleu, X., Mateos, M.-V., Usmani, S. Z., Nooka, A. K., Goldrick, A., Najdi, R., Shu, N., Facon, T.
Publicado 2022

P846: EXPRESSION SIGNATURE OF TP53 BIALLELIC INACTIVATION IDENTIFIES A GROUP OF MULTIPLE MYELOMA PATIENTS WITHOUT THIS GENETIC CONDITION BUT WITH DISMAL OUTCOME.

por De Ramón, C., Rojas, E. A., Cardona-Benavides, I. J., Mateos, M. V., Corchete, L. A., Gutiérrez, N. C.
Publicado 2022

Three-dimensional photographic analysis of the face in European adults from southern Spain with normal occlusion: reference anthropometric measurements

por Menéndez López-Mateos, M. L., Carreño-Carreño, J., Palma, J. C., Alarcón, J. A., Menéndez López-Mateos, C., Menéndez-Núñez, M.
Publicado 2019

PTTG2 silencing results in induction of epithelial-to-mesenchymal transition and apoptosis

por Méndez-Vidal, C, Gámez-Del Estal, M del Mar, Moreno-Mateos, M A, Espina-Zambrano, Á G, Torres, B, Pintor-Toro, J A
Publicado 2013

PB2020: MAJESTEC-3: RANDOMIZED, PHASE 3 STUDY OF TECLISTAMAB PLUS DARATUMUMAB VERSUS DPD OR DVD IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA

por Mateos, M. V., Bahlis, N., Costa, L., Perrot, A., Pei, L., Rubin, M., Lantz, K., Sun, W., Jaffe, M., Kobos, R., Nooka, A.
Publicado 2022

Management of relapsed and refractory multiple myeloma: novel agents, antibodies, immunotherapies and beyond

por Chim, C S, Kumar, S K, Orlowski, R Z, Cook, G, Richardson, P G, Gertz, M A, Giralt, S, Mateos, M V, Leleu, X, Anderson, K C
Publicado 2018

Correction: Management of relapsed and refractory multiple myeloma: novel agents, antibodies, immunotherapies and beyond

por Chim, C. S., Kumar, S. K., Orlowski, R. Z., Cook, G., Richardson, P. G., Gertz, M. A., Giralt, S., Mateos, M. V., Leleu, X., Anderson, K. C.
Publicado 2019

P24: EXPERT PERSPECTIVES OF UNMET NEED IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM) WHO RECEIVE LENALIDOMIDE-SPARING REGIMENS IN EUROPE

por Mateos, M, Leleu, X, Zamagni, E, Delforge, M, Bringhen, S, Broijl, A, de la Rubia, J, Shaw, A, Brescianini, A, Gonzalez-McQuire, S, Patel, S, Moreau, P
Publicado 2022

Papel del rinovirus en las infecciones respiratorias en niños hospitalizados

por Calvo Rey, C., García García, M.ªL., Casas Flecha, I., Sánchez Mateos, M.F., Rodrigo García, G., de Cea Crespo, J.M.ª, Pérez-Breña, P.
Publicado 2006

P34 LIGHTHOUSE (OP-108): MELFLUFEN PLUS DARATUMUMAB (DARA) AND DEXAMETHASONE (DEX) VERSUS DARA IN RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM) REFRACTORY TO AN IMMUNOMODULATORY DRUG...

por Mateos, M, Szarejko, M, Bila, J, Schjesvold, F, Spicka, I, Maisnar, V, Jurczyszyn, A, Grudeva-Popova, Z, Hajek, R, Usenko, G, Thuresson, M, Norin, S, Jarefors, S, Richardson, P, Pour, L
Publicado 2023

Efficacy and safety of carfilzomib regimens in multiple myeloma patients relapsing after autologous stem cell transplant: ASPIRE and ENDEAVOR outcomes

por Hari, P, Mateos, M-V, Abonour, R, Knop, S, Bensinger, W, Ludwig, H, Song, K, Hajek, R, Moreau, P, Siegel, D S, Feng, S, Obreja, M, Aggarwal, S K, Iskander, K, Goldschmidt, H
Publicado 2017

P972: INDIRECT COMPARISON OF TECLISTIMAB IN MAJESTEC-1 VERSUS PHYSICIAN’S CHOICE OF THERAPY IN LONG-TERM FOLLOW-UP OF TRIPLE-CLASS EXPOSED RELAPSED/REFRACTORY MULTIPLE MYELOMA IN D...

por Weisel, K., Chari, A., Usmani, S. Z., Goldschmidt, H., Mateos, M.-V., Qi, K., Londhe, A., Nair, S., Lin, X., Pei, L., Ammann, E., Kobos, R., Smit, J., Parekh, T., Slavcev, M., Moreau, P.
Publicado 2022

P935: REAL WORLD COMPARATIVE ANALYSIS OF THE EFFICACY OF TECLISTAMAB VERSUS CURRENT TREATMENTS IN PATIENTS WITH TRIPLE-CLASS EXPOSED RELAPSED/REFRACTORY MULTIPLE MYELOMA FROM THE L...

por Einsele, H., Moreau, P., Delforge, M., van de Donk, N. W., Ghilotti, F., Diels, J., Elsada, A., Strulev, V., Pei, L., Kobos, R., Smit, J., Slavcev, M., Weisel, K., Mateos, M.-V.
Publicado 2022

P1463: PHASE I DOSE ESCALATION OF LAVA-051, A NOVEL BISPECIFIC GAMMA-DELTA T-CELL ENGAGER (GAMMABODY™), IN RELAPSED/REFRACTORY HEMATOLOGICAL MALIGNANCIES

por Broijl, A., van de Donk, N., Bosch, F., Mateos, M. V., Rodriguez-Otero, P., Tucci, A., Ghia, P., Adang, A., Parren, P., Tuinhof, I., Umarale, S., Winograd, B., van der Vliet, H., Kater, A.
Publicado 2022